Form 4: Gilead Sciences CFO Andrew Dickinson Reports Routine Stock Transactions

Gilead Sciences, Inc.'s Chief Financial Officer, Andrew D. Dickinson, reported the acquisition of common stock through the vesting of restricted stock units and the subsequent disposition of shares for tax withholding purposes.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), reported changes in his beneficial ownership of company securities.
• On June 10, 2025, Mr. Dickinson acquired 3,694 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 1,758 shares of common stock were disposed of at a price of $110.09 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Dickinson directly beneficially owns 167,610 shares of common stock.
• He also directly beneficially owns 34,915 Restricted Stock Units.
• The Restricted Stock Units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter until fully vested.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a routine transaction, the executive's continued significant ownership of company stock and RSUs is a positive signal of alignment with shareholder interests. There are no negative implications from the reported transactions.

Positives

• The vesting of Restricted Stock Units for the Chief Financial Officer indicates a routine component of executive compensation, aligning management's interests with shareholders.
• The executive's continued significant direct ownership of 167,610 common shares and 34,915 RSUs demonstrates ongoing commitment to the company's performance.

Negatives

• The disposition of 1,758 shares was for tax withholding purposes, which is a standard practice upon equity award vesting and not indicative of a negative outlook on the company.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction. It solely reports past insider transactions.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where equity awards are a significant component of remuneration. It does not reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The structure of executive equity compensation, including Restricted Stock Units with multi-year vesting schedules, is a common practice in the biotechnology and pharmaceutical industries, similar to companies like Pfizer, Merck, or Johnson & Johnson.
• The disposition of shares to cover tax obligations upon vesting is a standard and expected procedure for equity awards across all industries, aligning with typical compensation and tax compliance practices.

Stakeholder Impact

• Shareholders: The transaction reflects a standard component of executive compensation, which aligns the Chief Financial Officer's financial interests with the long-term performance of the company, potentially benefiting shareholders.

Next Steps

• The remaining 34,915 Restricted Stock Units held by Mr. Dickinson will continue to vest according to their four-year schedule, with 6.25% vesting quarterly after the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Gilead Sciences, GILD, Form 4, Insider Transaction, Stock Ownership, Executive Compensation, Restricted Stock Units, CFO, Equity Vesting